Anti-EGFR and radiotherapy;Anti-REGF et radiothérapie

Cancer/Radiotherapie

Volumn 8, Issue 6, 2004, Pages 380-382

  Milano, G ^a   Magne N ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Apoptose; Apoptosis; Ciblage th rapeutique; EGFR; Radiotherapy; Radioth rapie; REGF; Therapeutic targeting

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL FUNCTION; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DRUG TARGETING; ENZYME INHIBITION; HUMAN; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

EID: 11144298617     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2004.09.002     Document Type: Short Survey

References (22)

1. D. Bandyopadhyay, M. Mandal, L. Adamn, J. Mendelsohn, and R. Kumar Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells J. Biol. Chem. 273 1998 1568 1573
2. C. Bianco, R. Bianco, G. Tortora, V. Damiano, P. Guerrieri, and P. Montemaggi Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide Clin. Cancer Res. 6 2000 4343 4350
3. C. Bianco, G. Tortora, R. Bianco, R. Caputo, B.M. Veneziani, and R. Caputo Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor. ZD1839 (Iressa) Clin. Cancer Res. 8 2002 3250 3258
4. A. Chakravarti, W. Seiferheld, I. Robbins, A. Guha, P. Sperduto, and A. Choucair Phase I results from RTOG BR-0211, a phase I/II study of an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (Iressa), with radiation therapy in glioblastoma multiforme (GBM) Int. J. Radiat. Oncol. Biol. Phys. 57 2003 S329
5. F. Ciardiello, R. Caputo, G. Borriello, D. Del Bufalo, A. Birocchio, and G. Zupi ZD1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in BCl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells Int. J. Cancer 98 2002 463 469
6. P. Dent, D.B. Reardon, J.S. Park, G. Bowers, C. Logsdon, and K. Valerie Radiation-induced release of transforming growth factor & activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death Mol. Biol. Cell 10 1999 2493 2506
7. S.M. Huang, J.M. Bock, and P.M. Harari Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck Cancer Res. 59 1999 1935 1940
8. S.M. Huang, and P.M. Harari Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis Clin. Cancer Res. 6 2000 2166 2174
9. S.M. Huang, J. Li, E.A. Armstrong, and P.M. Harari Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa) Cancer Res. 62 2002 4300 4306
10. P.A. Jeggo DNA-PK: at the cross-roads of biochemistry and genetics Mutat. Res. 384 1997 1 14
11. G. Lammering, T.H. Hewit, W.T. Hawkins, J.N. Contessa, D.B. Reardon, and P.S. Lin Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization J. Natl. Cancer Inst. 93 2001 921 929
12. G. Lammering, T.H. Hewit, K. Valerie, J.N. Contessa, G.P. Amorino, and P. Dent EGFRvIII-mediated radioresistance through a strong cytoprotective response Oncogene 22 2003 5545 5553
13. B. Liu, M. Fang, M. Schmidt, Y. Lu, J. Mendelsohn, and Z. Fan Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity Br. J. Cancer 82 2000 1991 1999
14. N. Magń, J.L. Fischel, A. Dubreuil, P. Formento, S. Marcie, and J.L. Lagrange Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer Br. J. Cancer 86 2002 819 827
15. N. Magń, J.L. Fischel, C. Tiffon, P. Formento, A. Dubreuil, and N. Reńe Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil British Journal of Cancer 89 2003 585 592
16. M. Mandal, L. Adam, J. Mendelsohn, and R. Kumar Nuclear targeting of Bax during apoptosis in human colorectal cancer cells Oncogene 17 1998 999 1007
17. F. Robert, M.P. Ezekiel, S.A. Spencer, R.F. Meredith, J.A. Bonner, and M.B. Khazaeli Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer J. Clin. Oncol. 19 2001 3234 3243
18. M.N. Saleh, K.P. Raisch, M.A. Stackhouse, W.E. Grizzle, J.A. Bonner, and M.S. Mayo Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation Cancer Biother. Radiopharm. 14 1999 451 463
19. S. Shintani, C. Li, M. Mihara, N. Terakado, J. Yano, and K. Nakashiro Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer Int. J. Cancer 107 2003 1030 1037
20. K.J. Williams, B.A. Telfer, I.J. Stratford, and S.R. Wedge ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model Br. J. Cancer 86 2002 1157 1161
21. R.D. Wood, M. Mitchell, J. Sgouros, and T. Lindahl Human DNA repair genes Science 291 2001 1284 1289
22. D. Ye, J. Mendelsohn, and Z. Fan Augmentation of a humanized anti-HER2 m Ab 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225 Oncogene 18 1999 731 738